Gaboxadol

Gaboxadol

Clinical data
Other names	THIP; 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol; LU-2-030; OV101; OV-101
Routes of administration	Oral[1]
Drug class	GABAA receptor agonist; Sedative; Hypnotic; Central depressant; Hallucinogen
ATC code	None
Identifiers
IUPAC name 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3(2H)-one
CAS Number	64603-91-4 Y
PubChem CID	3448
IUPHAR/BPS	4322
ChemSpider	3330 Y
UNII	K1M5RVL18S
KEGG	D04282 Y
ChEMBL	ChEMBL312443 Y
CompTox Dashboard (EPA)	DTXSID0045206
ECHA InfoCard	100.059.039
Chemical and physical data
Formula	C6H8N2O2
Molar mass	140.142 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C1/C2=C(\ON1)CNCC2
InChI InChI=1S/C6H8N2O2/c9-6-4-1-2-7-3-5(4)10-8-6/h7H,1-3H2,(H,8,9) Y Key:ZXRVKCBLGJOCEE-UHFFFAOYSA-N Y
(verify)

Gaboxadol, also known as 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP), as well as by its former developmental code names LU-2-030 and OV101, is a conformationally constrained derivative of the alkaloid and Amanita muscaria constituent muscimol.^[1][2] It acts as a direct GABA_A receptor agonist.^[1] At lower doses, the drug has sedative and hypnotic effects, and at higher doses, it has hallucinogenic effects.^[1][3][2][4] Gaboxadol was studied for potential medical use as a pharmaceutical drug for a variety of indications, most notably treatment of insomnia, but was ultimately never marketed.^[1][2]